Gilead Sciences, Inc. (NASDAQ:GILD)

CAPS Rating: 4 out of 5

A biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.

Results 1 - 20 of 332 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar warrenout (99.08) Submitted: 8/26/2014 8:33:10 PM : Underperform Start Price: $106.55 GILD Score: -0.90

Short-term short of a great company that's a bit ahead of itself at the moment

Recs

0
Member Avatar simplemts (< 20) Submitted: 8/26/2014 3:16:04 PM : Underperform Start Price: $106.10 GILD Score: -1.35

Bubble !

Recs

0
Member Avatar irondistance (< 20) Submitted: 8/25/2014 3:30:51 PM : Outperform Start Price: $107.20 GILD Score: +0.14

SOVALDI

Recs

0
Member Avatar Stigshift (21.92) Submitted: 8/22/2014 3:26:17 PM : Outperform Start Price: $74.85 GILD Score: +36.44

real money pick

Recs

0
Member Avatar OklaBoston (68.61) Submitted: 8/13/2014 4:32:17 PM : Outperform Start Price: $108.06 GILD Score: -0.56

"Bull Of The Day" at http://www.zacks.com

Recs

0
Member Avatar Toady (< 20) Submitted: 8/2/2014 11:44:47 PM : Outperform Start Price: $92.00 GILD Score: +12.92

Creating products that CURE people not just treat them (Hep C). Strong company with solid fundamentals. Very cheap stock with a ton of room to grow. Look at their pipeline, this company cares about growth and increasing value to their shareholders.

Recs

0
Member Avatar mrfore4471 (49.28) Submitted: 7/30/2014 12:01:52 PM : Outperform Start Price: $93.71 GILD Score: +12.58

When you create a drug that totally cures (in 98% of cases) a disease such as hepititas C, you know you've done something good. I hesitate extending the time frame because there seems to be some competitors who will probably accomplish this and for a cheaper price. In any case one of the research firms thinks this stock could hit $140.00 which obviously is pretty good.

Recs

1
Member Avatar shotgun06 (< 20) Submitted: 7/23/2014 4:20:17 PM : Outperform Start Price: $91.56 GILD Score: +16.60

Look at the products that they have and have in trials. The need for these products are very large!

Recs

1
Member Avatar shroff33 (< 20) Submitted: 7/20/2014 5:01:33 PM : Outperform Start Price: $89.80 GILD Score: +18.01

GILD will prevail over competition from ABBV and MRK.

Recs

0
Member Avatar zzgorch (41.24) Submitted: 6/30/2014 2:13:05 PM : Outperform Start Price: $83.38 GILD Score: +26.68

Strong EPS, well below market Forward P/E (10.72) and a PEG well under one (0.46). Gilead is finding actual cures for nasty diseases (Hepatitis C) and has HUGE upside potential. Wish I had the funds to buy on the drop early this spring but there is plenty of room to run. It should get up to 100 by year end.

Recs

0
Member Avatar bdescent (69.69) Submitted: 6/27/2014 8:37:32 PM : Outperform Start Price: $82.79 GILD Score: +27.37

Nice pipeline.

Recs

0
Member Avatar rbitrage (57.79) Submitted: 6/22/2014 9:20:14 PM : Outperform Start Price: $81.27 GILD Score: +29.98

Sovaldi. In spite of the fact charging so much for a drug should be illegal, it isn't. Gilead recognizes this and making a mint. Sovaldi actually cures Hep-C (most of the time) and the bad press has been fantastic advertising. Our country might go broke paying for drugs like this, but in the meantime, companies like Gilead will be laughing- all the way to the bank.

Recs

0
Member Avatar Investinguppy (< 20) Submitted: 6/17/2014 11:01:54 PM : Outperform Start Price: $79.85 GILD Score: +31.73

Solvaldi will surprise to the upside and is first to market. Promising pipeline.

Recs

0
Member Avatar iksnamyzs (79.86) Submitted: 6/16/2014 5:45:51 PM : Outperform Start Price: $80.73 GILD Score: +29.84

high but higher still

Recs

0
Member Avatar Jmaltsman (62.23) Submitted: 6/10/2014 5:05:46 PM : Outperform Start Price: $79.36 GILD Score: +32.60

Great company with large international presence. The stock is undervalued relative to forecasted revenue growth.

Recs

0
Member Avatar coachtom4 (75.74) Submitted: 6/9/2014 11:09:07 AM : Outperform Start Price: $78.83 GILD Score: +33.94

Assuming they come even close to analysts projections of earnings, they will have a single digit P/E in 19 months with significant growth.

Recs

0
Member Avatar cajun1958 (30.40) Submitted: 5/25/2014 12:52:16 PM : Underperform Start Price: $82.08 GILD Score: -26.04

They have the HIV & HCV treatments down but beed something new. HCV & HIV are common diseases and there is a huge market but as patents begin to expire, GILD becomes another ENDO or GSK.

Recs

0
Member Avatar 10x2 (29.64) Submitted: 5/15/2014 12:28:27 PM : Outperform Start Price: $79.89 GILD Score: +27.25

Mega growth story.

Recs

0
Member Avatar investomania (88.17) Submitted: 5/14/2014 9:56:14 PM : Outperform Start Price: $81.02 GILD Score: +26.43

Sometimes investing is simple. Revenues and profits are ramping up dramatically due to the best cure for Hepatitis C and the best preventative medication against HIV infection. Thanks to the recent pullback in all things biotech, the price is right. There's limited downside and a lot of room to run.

Recs

0
Member Avatar km00nster (< 20) Submitted: 5/8/2014 7:57:00 PM : Outperform Start Price: $71.71 GILD Score: +41.08

Very Very Very under-valued stock that should outperform in the long-term. If I was to put all my money into one stock, this would be it.

Featured Broker Partners


Advertisement